What is the 13F Pro Quality Score for MASI?

13F Pro ranks MASIMO CORP (MASI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MASI's current score at https://13fpro.ai/company/MASI (free sign-up required for the full ranking).

Where does 13F Pro source MASI data?

All MASIMO CORP fundamentals and ownership data come directly from SEC EDGAR. MASIMO CORP files with the SEC under CIK 937556. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MASI in?

MASIMO CORP (MASI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MASI research updated on 13F Pro?

MASI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MASIMO CORP(MASI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 937556 MASI stock profile & AI dashboard →

13F Pro Quality Score

55.9/100

Rank #1,215 of 2,962 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

45.4/100

Profitability

63.0/100

Balance Sheet

64.5/100

Earnings Quality

90.2/100

Free Cash Flow

62.7/100

Institutional Flow

0.1/100

Revenue Scale

58.7/100

Dilution Risk

37.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why MASI Scores 57/100

exact factor attribution · 2026-08-29

MASI's composite is driven by earnings quality and scale, held back by institutional flow and earnings growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings quality

+4.0 pts

90th pct

Scale

+1.8 pts

62th pct

Capital efficiency

+1.7 pts

67th pct

Profitability

+1.7 pts

61th pct

Free cash flow

+1.6 pts

60th pct

Revenue growth

+0.6 pts

53th pct

Shareholder dilution

-0.6 pts

37th pct

Earnings growth

-1.0 pts

30th pct

Institutional flow

-2.5 pts

0th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

MASI Stock Analysis & AI Quality Score

Data updated 2026-08-29

AI stock analysis and institutional research for MASIMO CORP (MASI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MASI at 55.9/100 on a 32-signal composite quality model, placing it at rank #1,215 of 2,962 stocks — the top half of the AI-ranked universe. MASI scores in the top quartile across earnings quality (90.2). Areas of concern include institutional flow (0.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 37.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), MASIMO CORP reports quarterly revenue of $403.6M, net income of $57.1M, an operating margin of 19.2%. Top institutional holders of MASI by reported 13-F value include BlackRock, Politan Capital Management, Pentwater Capital Management, based on the most recent SEC filings. MASI trades on the Nasdaq exchange and files with the SEC under CIK 937556. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MASI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MASIMO CORP directly from SEC EDGAR. MASIMO CORP's 13F Pro composite quality score has ranged between 33 and 72 since 2021, currently 55.9 — a declining long-term trajectory across 67 quarterly and live scoring snapshots.

✦

Fun facts about MASIMO CORP

Quirks, history, and lore behind MASI — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical technology company · mid-cap · listed on Nasdaq · headquartered in Southern California.
2
The Numbers
Annual revenue in the range of roughly $2 billion, built almost entirely on selling hardware, sensors, and software to hospitals that need to monitor patients continuously.
3
The History
Founded in the late 1990s, it spent years fighting a high-profile patent battle against a much larger rival — and won a landmark verdict that put the industry on notice.
4
The Secret
Its core innovation was reinventing pulse oximetry — the little clip that reads your blood oxygen — to work accurately even on patients in motion or with poor circulation.
5
The Lore
Its founder and CEO made headlines by purchasing a famous consumer audio brand, sparking a messy boardroom battle with investors who thought he'd gone wildly off-script.
6
The Giveaway
If you've ever had a rainbow-colored sensor clipped to your finger in a hospital, there's a good chance it said "SET" technology on the box — this Irvine company owns that standard.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$403.6M

Net Income

Q1 2026

$57.1M

Free Cash Flow

Q1 2026

$41.0M

Operating Margin

Q1 2026

19.2%

ROIC

Q1 2026

24.7%

D/E Ratio

Q1 2026

0.59

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+9.4% YoY

$1.53BFY 2025

FY22 $2.04BFY23 $1.28BFY24 $1.40BFY25 $1.53B

Net Income

+50.3% YoY

$-151.5MFY 2025

FY22 $143.5MFY23 $81.5MFY24 $-304.9MFY25 $-151.5M

Operating Income

+392.1% YoY

$310.0MFY 2025

FY22 $210.0MFY23 $166.0MFY24 $63.0MFY25 $310.0M

EPS (Diluted)

+50.0% YoY

$-2.80FY 2025

FY22 $2.60FY23 $1.51FY24 $-5.60FY25 $-2.80

Total Assets

-35.3% YoY

$1.70BFY 2025

FY22 $3.21BFY23 $3.04BFY24 $2.63BFY25 $1.70B

Total Debt

-32.5% YoY

$536.9MFY 2025

FY22 $986.9MFY23 $974.6MFY24 $795.2MFY25 $536.9M

Op. Cash Flow

+10.9% YoY

$217.8MFY 2025

FY22 $29.4MFY23 $94.1MFY24 $196.4MFY25 $217.8M

Free Cash Flow

+13.2% YoY

$198.4MFY 2025

FY22 $-23.4MFY23 $55.7MFY24 $175.3MFY25 $198.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.53B +9.4%	$1.40B +9.4%	$1.28B -37.3%	$2.04B +64.3%	$1.24B +8.3%	$1.14B
Net Income	$-151.5M +50.3%	$-304.9M -474.1%	$81.5M -43.2%	$143.5M -37.5%	$229.6M -4.5%	$240.3M
Operating Income	$310.0M +392.1%	$63.0M -62.0%	$166.0M -21.0%	$210.0M -23.9%	$275.8M +7.8%	$255.8M
EPS (Diluted)	$-2.80 +50.0%	$-5.60 -470.9%	$1.51 -41.9%	$2.60 -34.7%	$3.98 -3.9%	$4.14
Total Assets	$1.70B -35.3%	$2.63B -13.7%	$3.04B -5.3%	$3.21B +70.1%	$1.89B +10.2%	$1.71B
Total Debt	$536.9M -32.5%	$795.2M -18.4%	$974.6M -1.2%	$986.9M	$0.00	—
Operating Cash Flow	$217.8M +10.9%	$196.4M +108.7%	$94.1M +220.1%	$29.4M -88.9%	$264.6M +25.3%	$211.1M
Free Cash Flow	$198.4M +13.2%	$175.3M +214.7%	$55.7M +338.0%	$-23.4M -109.8%	$239.1M +72.5%	$138.6M

Get alerted when MASI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MASIMO CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MASI

BlackRock, Inc.
$826.1M4,644,578 sh
Politan Capital Management LP
$816.4M4,589,648 sh
Pentwater Capital Management LP
$564.9M3,176,000 sh
BARCLAYS PLC
$488.1M2,743,985 sh
HBK INVESTMENTS L P
$458.2M2,576,109 sh
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$416.7M2,342,790 sh
VANGUARD CAPITAL MANAGEMENT LLC
$364.6M2,050,045 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$357.0M2,006,861 sh
FMR LLC
$258.1M1,450,823 sh
STATE STREET CORP
$255.7M1,437,724 sh

Fund	Value	Shares
BlackRock, Inc.	$826.1M	4,644,578
Politan Capital Management LP	$816.4M	4,589,648
Pentwater Capital Management LP	$564.9M	3,176,000
BARCLAYS PLC	$488.1M	2,743,985
HBK INVESTMENTS L P	$458.2M	2,576,109
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$416.7M	2,342,790
VANGUARD CAPITAL MANAGEMENT LLC	$364.6M	2,050,045
VANGUARD PORTFOLIO MANAGEMENT LLC	$357.0M	2,006,861
FMR LLC	$258.1M	1,450,823
STATE STREET CORP	$255.7M	1,437,724

Companies Similar to MASI

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

APLS

Apellis Pharmaceuticals, Inc.

AI score

Very similar · 1 shared holders

CIBRA Capital Ltd

SNCY

Sun Country Airlines Holdings, LLC

AI score

Very similar · 1 shared holders

CIBRA Capital Ltd

HOLX

HOLOGIC INC

AI score

Very similar · 2 shared holders

CIBRA Capital Ltd Laird Norton Wetherby Wealth Management, LLC

ACLX

Arcellx, Inc.

AI score

Very similar · 1 shared holders

CIBRA Capital Ltd

MCW

Mister Car Wash, Inc.

AI score

Shared smart-money ownership · 1 shared holders

CIBRA Capital Ltd

FOLD

AMICUS THERAPEUTICS, INC.

AI score

Similar quality profile · 1 shared holders

CIBRA Capital Ltd

OneStream, Inc.

AI score

Shared smart-money ownership · 1 shared holders

CIBRA Capital Ltd

DHIL

DIAMOND HILL INVESTMENT GROUP INC

AI score

Shared smart-money ownership · 1 shared holders

CIBRA Capital Ltd

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MASI on your watchlist

Track score changes the day MASIMO CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MASI a good stock to buy?

13F Pro's AI-powered analysis of MASIMO CORP (MASI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MASI are available on the MASI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MASI is classified as a mid company.

Which hedge funds own MASI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MASI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MASIMO CORP's investment landscape.